A team of researchers at Indiana University (IU) published significant research findings via preprint server in ChemRxiv demonstrating for the first time that COVID-19 are killed upon exposure to an electroceutical fabric. Electroceutical refers to a matrix of embedded microcell batteries that creates an electric field and wirelessly generates a low level of electricity in the presence of moisture. The IU team has been busy generating the foundational evidence of the electroceutical fabric’s mechanism of action and use over the last six years. The recent results evidence the ability to eradicate SARS-CoV-2 pathogen within one minute of contact with the fabric, which disrupts the electrostatic forces the virus needs. The IU data reveals that even the novel coronavirus is killed by exposure to the low-level electric field-generating fabric, currently un use as a broad-spectrum antimicrobial wound care dressing. The team now actively seeks an approval via the FDA Emergency Use Authorization program to apply use of the fabric specifically for face masks in the fight against COVID-19. Present-day face masks have little to no ability to kill viruses or bacteria.
With nearly 5.5 million cases worldwide and 345, 981 deaths worldwide (the U.S. with now 99,219 deaths) as of May 24, the use of personal protective equipment, or PPE has become essential to safeguard health care providers against the novel coronavirus. COVID-19 particles that attach to PPE surfaces pose a significant threat to the spread of the virus.
Hence, the team of Indian University researchers sought to promptly publishing findings about the V.Dox technology breakthrough. This proprietary dox-matrix patterns of embedded microcell batteries creates an electric field and wirelessly produces a low level of electricity when moist. Coronaviruses rely on electrostatic interactions to be able to attach to their host and assemble themselves into an infective form. Their structure must remain stable to enable them to spread and hence infect. The IU team sought out to exploit the novel coronaviruses’ own electrokinetic characteristics in an attempt to dismantle their infectivity.
Part of the Solution Already Cleared
Apparently, the electroceutical dressing is FDA cleared and commercialized by a company called Vomaris Inc. The material is made of up of a polyester fabric printed with alternating circular meta dots consisting of elemental silver and zinc metals materializing moisture-activated microcell batteries.
IU Senior Author Comments
Chandan Sen, principal author of the study, and director of the Indiana Center for Regenerative Medicine and Engineering, part of the IU School of Medicine, commented, “This work presents the first evidence demonstrating that the physical characteristic features of coronaviruses may be exploited to render them non-infective following contact with low-level electric field-generating electroceutical fabric.” The Hoosiers goal now is to support Vomaris in its bid to receive an FDA Emergency Use Authorization” and that “we can utilize this fabric widely in the fight against COVID-19, ultimately saving lives,” noted Sen.
Based in Tempe, AZ, Vomaris specializes in bioelectric technology with the potential to revolutionize infection control and wound healing. Bioelectric technology from the company is the only platform in the world that powers a new generation of antimicrobial dressing for the wound and incisional care markets. Founded in 2004, the company has raised a total of $14.7 million according to website Crunchbase. The company employees under 20.
Indiana Center for Regenerative Medicine and Engineering
The IU Medicine School’s Indiana Center for Regenerative Medicine and Engineering is a multidisciplinary research center focused on the development of novel technologies that regenerate cells and tissues affected by age, disease, damage or congenital effects, ultimately leading to wound care and healing for patients in Indiana and beyond. Located on the Indiana University School of Medicine – Indianapolis campus, the center is comprised of more than 30 scientists and staff working to reduce the number of amputations in the state of Indiana and deliver critically acclaimed science.
Chandan Sen, Associate Vice President of Research, principal author of the study, and director of the Indiana Center for Regenerative Medicine and Engineering